Clinical Trials Browser

Neoplasms × Sorafenib × Clear all

NCT05468359 2026-05-19

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Phase 1/2 Recruiting

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03755791 2025-12-11

COSMIC-312

Phase 3 Active not recruiting

837 enrolled 14 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01754987 2025-05-04

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

Phase 1/2 Completed

5 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT02143401 2024-11-22

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Phase 1 Completed

Gastrointestinal

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms

NCT03582618 2023-01-10

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT00625378 2022-09-01

STEP

Phase 3 Completed

206 enrolled 17 charts

Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01271504 2021-05-12

E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma

Phase 1/2 Completed

102 enrolled 32 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01636908 2021-04-15

ICK

Phase NA Completed

Neoplasms

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Phase 1 Completed

Neoplasm Metastasis, Neoplasms, Recurrence

NCT02562755 2020-12-16

PHOCUS

Phase 3 Completed

459 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms, Vaccinia

NCT01264705 2020-11-12

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

Phase 1/2 Completed

47 enrolled 10 charts

Gastrointestinal

Fibrosis, Gastrointestinal Neoplasms, Hepatitis, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT00892424 2020-09-10

Sorafenib-RT Treatment for Liver Metastasis (SLIM)

Phase 1/2 Completed

Neoplasms

NCT00095459 2019-12-17

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

Phase 1 Completed

Neoplasms

NCT00610246 2019-02-15

A Study of Radiation With Sorafenib in Advanced Cancer

Phase 1 Completed

Neoplasms

NCT02636426 2018-10-22

SOPRANO

Phase 1 Completed

Neoplasms

NCT01189370 2017-06-01

Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer

Phase 2 Completed

25 enrolled 7 charts

Carcinoma, Renal Cell, Neoplasms

NCT02015728 2016-12-15

SEED

Phase NA Unknown

Neoplasms, Recurrence

NCT00811993 2016-11-02

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1 Terminated

Neoplasms

NCT01683149 2016-03-04

Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies

Phase 1 Completed

Neoplasms, Recurrence

NCT01585870 2015-10-27

Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of Sorafenib and Eribulin in Combination

Phase 1 Completed

Neoplasms

NCT00510250 2015-07-27

A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer

Phase 1/2 Completed

Carcinoma, Uterine Cervical Neoplasms, Neoplasms

NCT00110994 2015-06-08

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Phase 2 Completed

101 enrolled 21 charts

Melanoma, Neoplasms

NCT00449033 2015-04-23

NEXUS

Phase 3 Completed

904 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00352859 2014-12-30

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Phase 4 Terminated

Carcinoma, Renal Cell, Neoplasms

NCT00492986 2014-12-30

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

Phase 3 Completed

Carcinoma, Renal Cell, Neoplasms

NCT00657254 2014-12-23

Extension Program for Bay 43-9006

Phase 2 Completed

Neoplasm Metastasis, Neoplasms

NCT00079612 2014-12-19

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Phase 2 Completed

Carcinoma, Renal Cell, Neoplasms

NCT00259129 2014-11-13

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Phase 1 Completed

Neoplasms

NCT00105443 2014-10-31

SHARP

Phase 3 Completed

602 enrolled 14 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT00108953 2014-10-31

A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma

Phase 2 Completed

96 enrolled 18 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT00117637 2014-10-31

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Phase 2 Completed

189 enrolled 44 charts

Carcinoma, Renal Cell, Neoplasms

NCT00606125 2014-06-23

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Phase 1 Completed

Neoplasms

NCT00044512 2014-04-16

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Phase 2 Completed

137 enrolled 16 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT00398814 2014-02-19

Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers

Phase 1 Completed

GastrointestinalGenitourinary

Kidney Neoplasms, Liver Neoplasms, Neoplasms

NCT00073307 2014-02-06

Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer

Phase 3 Completed

903 enrolled 17 charts

Carcinoma, Renal Cell, Neoplasms

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

NCT00494299 2013-12-20

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Phase 3 Completed

458 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT00101400 2013-12-13

BAY43-9006 - Phase II in Advanced Breast Cancer

Phase 2 Completed

54 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT00562913 2013-11-26

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Phase 1 Completed

Neoplasms

NCT01069328 2013-11-13

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT00101413 2013-10-30

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Phase 2 Completed

52 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00110344 2013-10-11

Research Study for Patients With Metastatic Renal Cell Carcinoma

Phase 2 Terminated

Carcinoma, Renal Cell, Neoplasms

NCT00498836 2013-09-12

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Phase 2 Completed

Melanoma, Neoplasm Metastasis, Neoplasms

NCT00562523 2013-05-23

Sorafenib/Docetaxel Dose Escalation Trial

Phase 1 Completed

Neoplasms

NCT00613145 2013-02-04

Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Phase 3 Terminated

Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

NCT00098254 2012-05-02

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

Phase 2 Completed

37 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00882869 2011-07-13

XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Completed

Neoplasms